Formulation of Sustained-Release Ketorolac Tromethamine Pellets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation of Sustained-Release Ketorolac Tromethamine Pellets
The authors evaluated the effect of polymer composition on the drug-release profile and the effect of storage conditions on dissolution characteristics.


Pharmaceutical Technology
Volume 32, Issue 12, pp. 58-61

The observed release pattern from different pellets can be attributed to polymer permeability. The relatively higher permeability of Eudragit RL (16) to the dissolution medium could be considered responsible for the observed fast release of KT from the pellet coated only with Eudragit RL (see Figure 1). Including Eudragit RS, which is known to be of lower permeability (16), in the coat composition (Eudragit RL:Eudragit RS = 1:2) led to a reduction in drug release. Increasing the proportion of the less-permeable polymer Eudragit RS in the coating blend to 1:3 (Eudragit RL:Eudragit RS, respectively) resulted in a further reduction in drug release as a result of hindered permeation of the dissolution medium. This effect is most pronounced when the coat is made totally of Eudragit RS, where maximum retardation of drug release is observed (see Figure 1). Drug-release profiles also depend to a great extent on the integrity of the film surrounding the pellets, which is affected by the presence of plasticizer in the coating dispersion (17).

It seems from the present results that Formula III (Eudragit RL:Eudragit RS = 1:3) is of appropriate drug release such that the release of KT is extended over the test period in addition to a 100% release after 12 h. Although formula II and formula IV had similar release pattern, they showed only 92% and 86% release after 12 h. Therefore formula III was selected for the release kinetics study.

Release kinetics


Table II: The correlation coefficients and release rate constants of ketorolac tromethamine observed for zero-order, first-order, and Higuchi equation.
The release data from the selected pellets (Formula III) coated with Eudragit RL:Eudragit RS (1:3) were fitted to various release models (zero order, first order, and Higuchi models). Table II summarizes the correlation coefficients of these models. A plot of %-KT released over time (see Figure 1) indicated a nonlinear correlation, thereby suggesting that the release pattern from pellets doesn't follow the zero-order kinetic model. Drug release from Eudragit-coated pellets is expected to follow a diffusion-controlled model in accordance with the Higuchi equation (18).

The plot of the amount of KT released from pellets versus the square-root of time indicated that the amount of drug released increased linearly (r = 0.981) with the square-root of time. However, both the square-root of time and first-order release plot were linear, as indicated by the correlation coefficients derived from first-order and Higuchi equations (see Table II). The first-order release curve, however, showed biphasic release profiles with two distinct regions, in agreement with previous reports (19). The first region in the release occurs at a relatively fast rate (0.461 h–1), and a terminal region in which a reduction in drug release is observed (0.345 h–1) (see Table II). However, the Higuchi equation yielded a correlation coefficient value almost similar to that of the first-order equation (see Table II).

To further distinguish the exact mechanism of release, the differential form was performed. For a diffusion-controlled mechanism, the rate will be inversely proportional to the total amount of drug released Q, according to the following equation:

dQ/dt = K H 2 S 2/2Q

in which dQ/dt is the release rate, K H is the rate constant calculated from Higuchi equation, S is the surface area, and Q is the amount of drug released. The plot of release rate (dQ/dt ) versus 1/Q was linear (r = 0.994), indicating that the release of KT from the pellets was governed by the Higuchi square-root of time kinetics equation.

It could, therefore, be concluded that the apparent release of KT from the prepared pellets coated with Eudragit RL:Eudragit RS 1:3 appears to follow both diffusion-controlled and first-order kinetics. However, differential rate treatment confirmed that release was governed by a diffusion-controlled mechanism.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here